Constitutional Rho-kinase regulates atrioventricular nodal conduction and ventricular repolarization of the canine heart

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 930-933

  Sugiyama, Atsushi ^a   Takahara, Akira ^b   Yatomi, Yutaka ^a   Satoh, Yoshioki ^b   Nakamura, Yuji ^b   Hashimoto, Keitaro ^b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NONE

Author keywords

Conduction; Coronary blood flow; Repolarization; Rho; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RHO KINASE;

ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BLOOD VESSEL TONE; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DOG; ENZYME ACTIVITY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; NONHUMAN; PRIORITY JOURNAL;

ACTION POTENTIALS; AMIDES; ANIMALS; ATRIOVENTRICULAR NODE; BUNDLE OF HIS; CORONARY CIRCULATION; DOGS; FEMALE; HEART CONDUCTION SYSTEM; HEART VENTRICLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES;

EID: 0038118326     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00015     Document Type: Article

References (9)

1. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-27.
2. Sah VP, Minamisawa S, Tam SP, et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest. 1999;103:1627-34.
3. Cachero TG, Morielli AD, Peralta EG, The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel. Cell. 1998;93:1077-85.
4. Sugiyama A, Yatomi Y, Takahara A, et al. Cardiac effects of a selective Rho-associated kinase inhibitor, Y-27632, assessed in canine isolated, blood-perfused heart preparations. Jpn J Pharmacol. 2002;88:359-61.
5. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-4.
6. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol. 2000;57:976-83.
7. Sugiyama A, Lurie KG, Efange SMN, et al. Direct cardiac effects of a novel vesamicol receptor ligand, m-iodobenzyl-trozamicol, assessed in the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol. 1999;34:843-7.
8. Sugiyama A, Lurie KG, Efange SMN, et al. Effects of a novel vesamicol receptor ligand, m-iodobenzyl-trozamicol, on the canine isolated, blood-perfused atrioventricular node preparation. Jpn J Pharmacol. 2000;82:144-9.
9. Motomura S, Iijima T, Taira N, et al. Effects of neurotransmitters injected into the posterior and the anterior septal artery on the automaticity of the atrioventricular junctional area of the dog heart. Circ Res. 1975;37:146-55.